Dexcom Inc
XMUN:DC4
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
D
|
Dexcom Inc
XMUN:DC4
|
US |
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
KR |
|
I
|
Inturai Ventures Corp
CNSX:URAI
|
CA |
|
H
|
Hyulim ROBOT Co Ltd
KOSDAQ:090710
|
KR |
|
I
|
Inchcape PLC
DUS:IJCA
|
UK |
|
Progyny Inc
NASDAQ:PGNY
|
US |
|
M
|
MMM Capital PCL
SET:MMM
|
TH |
|
Beijing Tong Ren Tang Co Ltd
SSE:600085
|
CN |
|
P
|
Procter & Gamble Co
XMUN:PRG
|
US |
|
Seri Industrial SpA
F:PCHP
|
IT |
|
C
|
Companias CIC SA
SGO:CIC
|
CL |
|
T
|
Teixeira Duarte SA
XMUN:TXC2
|
PT |
|
Eifelhoehen-Klinik AG
F:EIF
|
DE |
|
F
|
Flexdeal SIMFE SA
ELI:FLEXD
|
PT |
|
Procter & Gamble Co
NYSE:PG
|
US |
Ergebniskonferenzen
Letzter Earnings Call
Revenue: Dexcom reported second-quarter revenue of $1.31 billion, up 13% year over year on a reported basis and 12% organically, with growth led by strong U.S. and international demand.
Guidance: Management raised full-year revenue guidance to $5.18 billion to $5.25 billion and also lifted gross margin, operating margin, and EBITDA margin targets.
Demand: New customer starts stayed at a record level globally, with a sequential uptick in the U.S. and broad-based strength across patient groups.
Coverage: The company said its CONNECT trial strengthens the case for broader reimbursement in non-insulin type 2 diabetes and that it has already submitted the data to CMS.
Products: Dexcom highlighted the launch of the redesigned Stelo app, progress on Smart Basal, the rollout of G7 15 Day, and Health Canada’s clearance of G7 15 Day.
Cash Return: Dexcom generated over $600 million of free cash flow in the first half and repurchased about $600 million of stock in Q2 under its $1 billion buyback plan.